COLL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Collegium Pharmaceutical Inc (COLL) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company shows promising growth potential in its financials and future projections, the recent insider selling, lack of significant trading signals, and bearish technical indicators suggest caution. The stock may be better suited for monitoring rather than immediate investment.
The technical indicators are mixed to bearish. The MACD is positive and expanding, but the RSI is neutral at 31.943, and the moving averages show a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level (S1: 32.091), with resistance levels far above the current price, indicating limited upward momentum in the short term.
Analysts have raised price targets recently, with targets ranging from $55 to $60, citing growth potential in the ADHD treatment sector and the durability of its pain portfolio.
The company reported strong financial growth in Q4 2025, with revenue up 12.92% YoY, net income up 35.31% YoY, and EPS up 28.57% YoY.
The $650 million acquisition of AZSTARYS reflects a strategic shift towards mental health treatments, which could drive long-term growth.
Insiders are selling shares, with a 145.95% increase in selling activity over the last month, which may indicate a lack of confidence in the near-term stock performance.
The stock experienced a regular market price decline of -2.83%, and pre-market change is -1.50%, reflecting weak short-term sentiment.
No recent congress trading data or influential figure purchases to support confidence in the stock.
In Q4 2025, Collegium Pharmaceutical showed strong financial performance with revenue increasing by 12.92% YoY to $205.45 million, net income growing by 35.31% YoY to $16.96 million, and EPS rising by 28.57% YoY to 0.45. Gross margin also improved significantly by 15.68% YoY to 62.49%. The company projects 2026 revenue between $805-$825 million, indicating strong growth potential.
Analysts remain positive on the stock, with multiple Buy and Overweight ratings. Recent price target updates include Truist raising the target to $58, H.C. Wainwright increasing it to $60, and Barclays adjusting it to $56. Analysts highlight the company's multi-year growth runway, Jornay momentum, and pain portfolio durability as key strengths.
